Story perspectives

Hims & Hers Stock: Mixed Ratings Amid Insider Sales

9/15/2025

48 5

Summary

Story summary

Canaccord Genuity rated Hims & Hers Health's stock as "buy," setting a price target of $68.00, suggesting a 22.57% upside.
Morgan Stanley targets $40.00, while Zacks downgraded the stock to "hold."
The stock opened at $55.48, with a market cap of $12.54 billion and a 12-month high of $72.98.
Institutional investors hold 63.52% of the company, with notable stakes from Centaurus Financial and Marex Group.
The company reported $544.83 million in revenue last quarter, slightly missing estimates, and insiders, including CEO Andrew Dudum, sold shares, reducing their holdings.

1 of 1

Story summary

Canaccord Genuity rated Hims & Hers Health's stock as "buy," setting a price target of $68.00, suggesting a 22.57% upside.
Morgan Stanley targets $40.00, while Zacks downgraded the stock to "hold."
The stock opened at $55.48, with a market cap of $12.54 billion and a 12-month high of $72.98.
Institutional investors hold 63.52% of the company, with notable stakes from Centaurus Financial and Marex Group.
The company reported $544.83 million in revenue last quarter, slightly missing estimates, and insiders, including CEO Andrew Dudum, sold shares, reducing their holdings.